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Forest Hills, New York to be a penetrating look at how psychiatrists approach and avoid genetic issues, given limited scientific expertise in this area. Advising patients about things we do not know much about ought to give us pause. We risk imposing our values on our patients. We are on soft moral ground when we do. I was struck by the responses to the pregnancy scenario (question 5 of the survey included in that study), in which respondents tackled the imaginary situation in which a fetus ran a quantifiable risk of developing various psychiatric conditions. Respondents then offered either nondirective counsel or advice to continue or terminate the pregnancy. With the exception of anencephaly, about 70% opted for nondirective information. I was surprised that psychiatrists recommended terminations in cases of autism (20%), Down syndrome (19%), schizophrenia (12%), and antisocial personality disorder (10%) as often as they did. Acknowledging the hypothetical nature of this scenario, it still is remarkable that these percentages are so high. This suggests to me that psychiatrists may be quicker to recommend termination than perhaps their patients and/or other physicians might suspect. Without question, these disorders can be profoundly distressing, disabling, and burdensome to those afflicted and those around them. Nevertheless, recommending termination of pregnancy in such cases is to equate it with anencephaly, a condition with a much more uniformly bleak prognosis.
The scenario does not address whether these doctors were to consider this a consultation with people who were not already their patients. I would suggest that directive information may be more easily made when there is no previous doctor-patient relationship. Clearly, this was a minority of respondents dealing with a circumstance that may never come to pass and can only be answered in the abstract. Some psychiatrists' experiences with these disorders could lead them to recommend termination out of compassion. That is a position worthy of respect, although physicians need to be particularly careful about using their professional authority in value-laden decisions.
I am not aware of any recent data concerning psychiatrists' attitudes toward abortion in general or in situations such as those the study attempts to explore. I speculate that psychiatrists tend to be more politically liberal and less religious than the general population. It may also be true that, as advocates for our own patients burdened by such a pregnancy in the context of mental illness, we may see termination as the better choice sometimes. The issue here is not about one's politics or one's religion; rather, it is about being honest about whether or not our recommendations are based on medical knowledge. Dr. Moldawsky notes that a substantial minority of respondents to our survey indicated they would provide directive counseling in response to a hypothetical scenario involving prenatal genetic testing. He expresses concern that, in some cases, counseling may be influenced by factors other than medical knowledge. We concur that psychiatrists should be aware, in all clinical encounters, of the limitations of their knowledge and ways that practice may be inappropriately influenced by personal biases. As he points out, the counseling scenario presented in our survey involving a highly predictive prenatal test may never become a clinical reality for many psychiatric disorders. Nevertheless, we believe our study highlights several issues that deserve attention if advances in genetics are to inform psychiatric practice. At a minimum, increased education of psychiatrists about genetics, including the complexities and limitations of our current understanding, will be important in the coming years.
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Electroencephalographic Abnormalities Associated With Antidepressant Treatment: A Comparison of Mirtazapine, Venlafaxine, Citalopram, Reboxetine, and Amitriptyline Sir: Abnormalities in electroencephalography (EEG) recordings may occur during treatment not only with antipsychotics, but also with antidepressants.
1,2 Mirtazapine and venlafaxine, 2 potent novel antidepressants that are regarded as being safer in terms of neurotoxic side effects compared to tricyclic antidepressants (TCAs), have recently been associated with a proconvulsant action. 3, 4 To compare the occurrence of EEG abnormalities during mirtazapine and venlafaxine treatment with EEG changes during treatment with antidepressants of other substance classes, including TCAs, we retrospectively analyzed EEG recordings of 255 patients undergoing antidepressant monotherapy with mirtazapine, venlafaxine, citalopram, reboxetine, or amitriptyline.
Method. Patients were diagnosed according to the International Classification of Diseases, 10th Revision (ICD-10), criteria (some patients had more than 1 diagnosis): 188 with a major depressive episode (ICD-10: F 31/32/33.xx); 39 with anxiety, obsessive-compulsive, adjustment/acute distress, or somatoform disorders (F 40/41/42/43/45.xx); 19 with schizophrenia or schizoaffective disorder (F 20/25.xx); 9 with dysthymia (F 34.1x); and 9 with personality disorders (F 60.xx). Digital EEGs recorded at wakeful resting states (≥ 20 minutes, including hyperventilation, no sleep tracings) were tracked using a Brain Vision Database (Version 0.93, Brain Products, Munich, Germany) and visually interpreted independently by 2 experienced raters (A.S., O.P.), one of whom was blind to medication, dosage, and diagnosis (A.S.). The findings were classified as normal or abnormal, i.e., with or without intermittent slow waves, slow posterior dominant rhythm, exaggerated response to hyperventilation, and epileptiform activity, as previously reported.
5
Results. Demographic characteristics of patients and the mean dosage of antidepressants are presented in Table 1 . Six patients in the mirtazapine group, 9 in the venlafaxine group, 4 in the citalopram group, none in the reboxetine group, and 5 in the amitriptyline group had abnormal EEG findings (Table 1) . Abnormal EEG patterns were intermittent slow waves (mirtazapine, citalopram, venlafaxine, and amitriptyline), slow posterior dominant rhythm (amitriptyline and mirtazapine), and exaggerated response to hyperventilation (amitriptyline, venlafaxine, and mirtazapine). No epileptiform activity was observed in any patient. The frequency of EEG abnormalities varied but was generally low (0% to 18%) and not statistically significantly different among groups (χ 2 = 7.54, df = 4, p = .11; N = 225). Patients with abnormal and patients with normal EEG patterns did not significantly differ by dosage. Only in the mirtazapine group was a statistical trend toward higher dosages in patients with EEG abnormalities found (p = .064).
In contrast to the extensive body of literature on the action of tricyclics and first-generation selective serotonin reuptake inhibitors (SSRIs) on EEG activity, 6,7 mirtazapine, venlafaxine, second-generation SSRIs, and reboxetine are less well studied in this respect. 8 Recently, mirtazapine was found to induce EEG abnormalities with epileptiform patterns in both healthy volunteers and depressed subjects at therapeutic levels, 3 and venlafaxine has been reported to provoke seizures in overdose (≥ 900 mg) at a higher rate than TCAs. 4 In the present study, intermittent slow-wave activity during treatment with venlafaxine, mir- tazapine, and citalopram was observed, but no epileptiform patterns occurred. Descriptively, there were clear differences in the frequency of EEG alterations between groups; however, these differences did not reach statistical significance. The retrospective design and moderate sample sizes limit a further interpretation of the data in this respect. It is remarkable that no EEG abnormalities were observed during reboxetine treatment. This observation converges with previous findings suggesting a favorable action of reboxetine on cognitive and psychomotor functions. 9, 10 In conclusion, the current study supports the safety of mirtazapine and venlafaxine in contrast to recent reports of epileptogenic activity. Prospective studies in larger sample sizes including at-risk patients, e.g., patients with cerebral disorders, are now needed to further assess the safety of antidepressants regarding their potential to induce EEG abnormalities. switch to topiramate. In view of the clinical experience of one of the authors (S.W.) in using topiramate for bipolar disorders, we proposed to stabilize the patient at 150 mg/day using a graded regimen with an initial dose of 25 mg/day, increasing by 25 mg weekly.
During topiramate treatment, the patient remained euthymic and lost 3 kg over 4 weeks. However, when 150 mg/day was reached, she experienced panic attacks that included shortness of breath, increased heart rate, and muscle tightness. She had no history of panic attacks before introduction of topiramate. The panic attacks stopped entirely 2 weeks after discontinuation of topiramate, and the patient refused further mood-stabilizing drugs. Two months after topiramate discontinuation, she experienced a hypomanic episode (DSM-IV criteria) without psychotic symptoms, which necessitated hospitalization. With the patient's compliance, topiramate was reintroduced by a psychiatrist who was skeptical about the association between panic attacks and topiramate. When the topiramate dose was increased from 100 to 150 mg/day (same dosing protocol), the patient again experienced panic attacks. The panic attacks disappeared 1 week after switching from topiramate to lamotrigine, 15 mg/day. The patient has remained euthymic since introduction of lamotrigine (4 months) and has experienced no further panic attacks. A detailed patient history allowed us to exclude interactions with other medication as an explanation of the panic attacks.
In a systematic review of the MEDLINE and Cochrane Library databases (range of years: 1970-2005; languages: English, French, and German; keywords: panic attack, topiramate, and anxiety), we found only 1 other case report of panic attacks associated with topiramate, 3 concerning a 24-year-old woman with bipolar II disorder. Panic attacks occurred when 50 mg/day of topiramate was added to treatment with 100 mg/day of lamotrigine; the panic attacks disappeared 2 weeks after discontinuation of topiramate, while treatment with lamotrigine monotherapy continued. A prospective study researching the prevalence of adverse psychiatric events in 103 patients with epilepsy treated with topiramate revealed that 10.7% of patients had affective disorders; 3.7%, psychotic disorders; 5.6%, aggressive behavior; and 3.9%, other behavior abnormalities such as agitated behavior, anger, or anxiety. 4 The carbonic anhydrase properties of topiramate could theoretically lead to CO 2 retention and trigger the occurrence of panic attacks in patients with a specific vulnerability. 5 Considering the elevated comorbidity of panic disorder associated with bipolar disorders, clinicians who treat patients with topiramate should pay special attention to the possibility of induction or exacerbation of panic attacks. More studies are warranted to elucidate individual differences between patients concerning the influence of topiramate on anxiety level, as well as differences in the neurobiological bases underlying individual anxiety disorders.
hydramine. His medication was changed to olanzapine, and symptoms did not recur.
Case 2. Ms. B, a 20-year-old African American woman, was hospitalized in August 2004 with irritability, disorganized thought, decreased need for sleep, increased energy, and moodcongruent delusions. She had been seen briefly in the past by the psychiatric emergency services of the University Hospital, but had not received sustained treatment since being diagnosed with bipolar disorder 2 years prior to her current presentation. Ziprasidone was started at 80 mg b.i.d. and continued for 2 days, until the patient was observed to have dystonia of her jaw and mouth. She received 2 mg of benztropine, with rapid resolution of symptoms. The patient was restarted on ziprasidone, without recurrence of her dystonic symptoms, and discharged. She was later readmitted with subsequent mood episodes, confirming her bipolar diagnosis.
A MEDLINE search using the keywords ziprasidone and dystonia revealed no previous reports of dystonic reactions in bipolar patients, either as single case reports or as part of a larger study, despite some previous observations of increased incidences of dystonia and extrapyramidal symptoms in patients with affective disorders. 14, 15 Our observation of 2 incidents of an acute dystonic reaction in bipolar patients during just 1 year suggests that dystonia may be underdiagnosed or at least underreported in affective, particularly manic, patients. Both of these cases occurred within a few days of rapid dose titration, as did 2 previously reported cases. 10, 12 Clinicians prescribing ziprasidone should be vigilant for dystonia in bipolar patients, particularly with rapid dose escalation.
In conclusion, because MPH patients represent a complex and difficult-to-treat patient population, ongoing assessment of differential diagnosis is critical. Tardive dystonia should be considered in the differential diagnosis of such a presentation of MHP.
